plerixafor has been researched along with Cancer, Second Primary in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Apperley, J; Blaise, D; Browne, P; Garderet, L; Iacobelli, S; Isaksson, C; Kobbe, G; Koster, L; Krejci, M; Kröger, N; Lenhoff, S; Ljungman, P; Morris, C; Muñiz, SG; Reményi, P; Russell, NH; Sahebi, F; Sanchez, JF; Sbianchi, G; Schaap, N; Scheid, C; Schönland, S; Trneny, M; Wiktor-Jedrzejczak, W; Wilson, KMO; Yakoub-Agha, I | 1 |
Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Deol, A; Lum, LG; Masood, A; Ratanatharathorn, V; Uberti, JP | 1 |
1 trial(s) available for plerixafor and Cancer, Second Primary
Article | Year |
---|---|
Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML.
Topics: Adult; Aged; Benzylamines; Compassionate Use Trials; Cyclams; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
1 other study(ies) available for plerixafor and Cancer, Second Primary
Article | Year |
---|---|
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.
Topics: Adult; Age Factors; Aged; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prospective Studies; Transplantation, Autologous; Young Adult | 2018 |